tiprankstipranks
Aligos Therapeutics Shareholders Back Key Corporate Resolutions
Company Announcements

Aligos Therapeutics Shareholders Back Key Corporate Resolutions

Pick the best stocks and maximize your portfolio:

The latest update is out from Aligos Therapeutics (ALGS).

At Aligos Therapeutics, Inc.’s Annual Meeting, stockholders authorized an increase of the company’s voting common stock from 300 million to 500 million shares and voted on five key proposals. These included the election of two Class I directors, ratification of Ernst & Young LLP as the auditor for the upcoming fiscal year, a potential reverse stock split, an amendment to the 2020 Plan regarding pre-funded warrants, and the aforementioned stock increase. The proposals were passed with a majority of votes, reflecting shareholder support for the company’s strategic decisions and governance.

Find detailed analytics on ALGS stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyAligos Therapeutics announces inducement grants under Nasdaq listing rule
TheFlyAligos Therapeutics down 8% after data presented at The Liver Meeting
TheFlyAligos Therapeutics trading resumes
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App